A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine

Key Inclusion Criteria: * Sex: Male or female; female subjects may be of childbearing potential, of nonchildbearing potential, or postmenopausal. * Age: ≥ 50 years of age at screening. * Status: Healthy subjects. * Subjects must agree to not be vaccinated with any HZ vaccine while participating in this study. * Subjects must agree to not be vaccinated with any RNA-based vaccines (e.g., Spikevax, Comirnaty, etc.) 30 days before Dose 1 through 30 days after Dose 2 (a 4-month period). Key Exclusion Criteria: * Subjects with a history of HZ within the past 10 years or current diagnosis of HZ. * Previous vaccination against HZ. * Subjects with any respiratory illness deemed clinically relevant by the Investigator within the past month OR hospitalization \>24 hours for any reason within the past month prior to the first vaccine administration (JCXH-105 or Shingrix). * Subjects who are acutely ill or febrile with body temperature ≥ 38.0º Celsius/100.4º Fahrenheit 72 hours prior to or at the Screening visit or on Day 1 pre-dose. Subjects meeting this criterion may be rescheduled within an allowable window with approval from the Sponsor. * Subjects with history or current diagnosis of congenital or acquired immunodeficiency/immunocompromising/immunosuppressive conditions, asplenia, or recurrent severe infections. Certain immune-mediated conditions (e.g., Hashimoto thyroiditis) that are well controlled and stable are allowed. * Subjects with history of myocarditis or pericarditis…